ClinicalTrials.gg
CompletedNCT00201955Updated Jun 24, 2026

Study of Rebamipide Eye Drops to Treat Dry Eye

A Phase 3 interventional study of Rebamipide 1% and Rebamipide 2% in Keratoconjunctivitis Sicca, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
762
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Keratoconjunctivitis Sicca with a site in United States — none open to participants now, none under way, none of them phase 3. Keratoconjunctivitis Sicca · United States.

Enrollment
3rd of 52
762 · median 100
Started
2004
with 3 others
Phase 3
13 of 56
none open now
Registered
4th of 56
by date
Lead sponsor
2 of 56
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, this one is the 3rd largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2004, is one of 13 in phase 3, and was the 4th registered.

Keratoconjunctivitis Sicca

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

Browse Keratoconjunctivitis Sicca studies →

Open to participants now

None of the 56 studies in Keratoconjunctivitis Sicca with a site in United States is open now. The open studies under Keratoconjunctivitis Sicca, anywhere →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 56 studies in Keratoconjunctivitis Sicca with a site in United States as a file.
02

Study summary

The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).

Read the detailed description

There is a need for effective therapy for dry eye that treats the underlying cause of the syndrome. The goal of this study is to assess the impact of rebamipide on dry eye symptoms.

03

Conditions studied

  • Keratoconjunctivitis Sicca

Keywords

  • dry eye
  • keratoconjunctivitis sicca
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must have symptoms of dry eye for a minimum of 6 months
  • must be able to sign and date an

Exclusion criteria

Exclusion Criteria:

  • presence of anterior segment disease
  • glaucoma or ocular hypertension
  • using Restasis
  • use of topically instilled ocular medications during study
  • use of contact lenses
  • history of ocular surgery within 12 months
  • females who are pregnant, breast feeding, or and not willing to remain abstinent or use
  • presence of Stevens-Johnson syndrome
  • any anticipated change in medication through-out study
  • concurrent involvement in another study or previous receipt of this drug
  • cannot be safely be weaned off of ocular medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
762 participants (actual)

Study arms

  • Active comparator
    Rebamipide 1%

    Participants will receive rebamipide 1% ophthalmic suspension four times daily (QID) for 26 weeks

    Drug: Rebamipide 1%

  • Active comparator
    Rebamipide 2%

    Participants will receive rebamipide 2% ophthalmic suspension four times daily (QID) for 26 weeks

    Drug: Rebamipide 2%

  • Placebo comparator
    Placebo

    Participants will receive a rebamipide-matching placebo ophthalmically four times daily (QID) for 26 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. fluorescein corneal staining (FCS) total score at week 12 and the average primary ocular discomfort (POD) severity score at week 12

    Time frame: 12 week

Secondary outcomes

  1. fluorescein corneal staining (FCS) total score at week 26 and the average primary ocular discomfort (POD) severity score at week 26

    Time frame: 26 week

07

Study locations

60 sites
  • Harold Helms, MD
    Birmingham, Alabama 35205, United States
  • Michael Bernstein, MD
    Birmingham, Alabama 35216, United States
  • I Care! Eye Care!
    Flagstaff, Arizona 860001, United States
  • Harvey and Bernice Jones Eye Institute
    Little Rock, Arkansas 72205, United States
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • Benchmark Research
    San Francisco, California 94102, United States
  • Southern California Clinical Research, Inc.
    San Marino, California 91108, United States
  • Colorado Eye Associates, PC
    Colorado Springs, Colorado 80907, United States
  • Danbury Eye Physicians and Surgeons, P.C.
    Danbury, Connecticut 06810-4005, United States
  • Florida Ophthalmic Institute
    Gainesville, Florida 32605-3192, United States
  • Florida Wellcare Alliance, L.C.
    Inverness, Florida 34452, United States
  • Shettle Eye Center
    Largo, Florida 33770, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Tukio Institute for Clinical Research
    North Miami Beach, Florida 33169, United States
  • Magnolia Research Group, Inc.
    Ocala, Florida 34471, United States
  • Radiant Research - West Palm Beach
    West Palm Beach, Florida 33407, United States
  • Vision Incorporated
    Savannah, Georgia 31406, United States
  • Welborn Clinic
    Evansville, Indiana 47714, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Wichita Clinic, PA
    Wichita, Kansas 67208, United States
  • Taustine Eye Center
    Louisville, Kentucky 40217, United States
  • Bossier Optical, Inc.
    Bossier City, Louisiana 71111, United States
  • Stevenson Medical Surgical Eye Center
    New Orleans, Louisiana 70119, United States
  • Family Eye Centers
    New Orleans, Louisiana 70127, United States
  • Ophthalmic Research Associates, Inc.
    North Andover, Massachusetts 01845, United States
  • Minnesota Eye Associates
    Minneapolis, Minnesota 55404, United States
  • Depremont Eye Specialists
    Gulfport, Mississippi 39507, United States
  • Opthalmology Associates
    Creve Coeur, Missouri 63141, United States
  • Clinical Research Laboratories
    Piscataway, New Jersey 08854, United States
  • Ophthalmology Associates
    Princeton, New Jersey 08540, United States
  • Eye Care Associates
    Bethpage, New York 11021, United States
  • Ophthmalmic Consultants of Long Island
    Lynbrook, New York 11563, United States
  • Mt. Sinai Medical Center School of Medicine
    New York, New York 10029, United States
  • Ophthalmic Consultants of Long Island
    New York, New York 11570, United States
  • Rochester Ophthalmological Group
    Rochester, New York 14618, United States
  • Ophthalmic Consultants of Long Island
    Valley Stream, New York 11581, United States
  • Western Wake Eye Center, P.A.
    Cary, North Carolina 27511, United States
  • Southeast Clinical Research Associates
    Charlotte, North Carolina 28210, United States
  • Horizon Eye Care - Clinical Research Dept.
    Charlotte, North Carolina 28211, United States
  • Cornerstone Research Care
    High Point, North Carolina 27262, United States
  • Carolina Eye Associates
    Southern Pines, North Carolina 28387, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Comprehensive Opthalmology & Optical Services
    Cleveland, Ohio 44115, United States
  • Bend Medical Clinic
    Bend, Oregon 97701, United States
  • Medical Eye Center
    Medford, Oregon 97504, United States
  • Valley Clinical Research Center
    Easton, Pennsylvania 18045, United States
  • Philadelphia Eye Associates
    Philadelphia, Pennsylvania 19148, United States
  • University of Pittsburg Eye and Ear Institute
    Pittsburgh, Pennsylvania 15233, United States
  • Glaucome-Cataract Consultants
    Pittsburgh, Pennsylvania 15243, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Total Eye Care, P.A.
    Memphis, Tennessee 38119, United States
  • Corona Research Consultants, Inc.
    El Paso, Texas 79904, United States
  • The University of Texas Medical Branch
    Galveston, Texas 77555, United States
  • Physician Research Network
    Houston, Texas 77002, United States
  • Houston, Texas 77002, United States
  • Medical Center Ophthalmology
    Houston, Texas 77030, United States
  • Houston Eye Associates
    Houston, Texas 77125, United States
  • Sun Research Institute
    San Antonio, Texas 78205, United States
  • Eye Clinic of South Texas
    San Antonio, Texas 78209, United States
  • Advanced Healthcare Clinical Research Center
    Milwaukee, Wisconsin 21209, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in Jul 2006, 26 months.

Of 12 phase 3 interventional studies under Keratoconjunctivitis Sicca, half reached primary completion within 14 months of starting (the median); a quarter within 7 and three quarters within 18. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
StartActual
May 1, 2004
Primary completionActual
Jul 1, 2006
CompletionActual
Jul 1, 2006
Results delay requested
Feb 19, 2014
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00201955
Collaborators
Novartis
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
May 1, 2004
Primary completion
Jul 1, 2006
Completion
Jul 1, 2006
Last update
Jun 24, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rebamipide

Start the discussion